305 related articles for article (PubMed ID: 23849582)
21. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
[TBL] [Abstract][Full Text] [Related]
22. [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre].
Khouaja K; Ben Sorba N; Bouslama A; Youssef A; Taher Mosbah A
Prog Urol; 2005 Apr; 15(2):255-9. PubMed ID: 15999603
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
[TBL] [Abstract][Full Text] [Related]
24. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
25. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
[TBL] [Abstract][Full Text] [Related]
26. [Screening for early detection of prostate cancer (first experience in Israel)].
Neheman A; Shotland Y; Metz Y; Stein A
Harefuah; 2001 Jan; 140(1):4-10, 88, 87. PubMed ID: 11242898
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
28. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for Diagnosis of Prostate Cancer.
Eur Urol; 1997; 32(2):133-9. PubMed ID: 9286642
[TBL] [Abstract][Full Text] [Related]
29. Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review.
Pepe P; Panella P; D'Arrigo L; Savoca F; Pennisi M; Aragona F
Oncology; 2006; 70(2):81-9. PubMed ID: 16601365
[TBL] [Abstract][Full Text] [Related]
30. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
[TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
Gosselaar C; Roobol MJ; Roemeling S; van der Kwast TH; Schröder FH
Prostate; 2007 Feb; 67(2):154-61. PubMed ID: 17044079
[TBL] [Abstract][Full Text] [Related]
32. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
Haroun AA; Hadidy AS; Awwad ZM; Nimri CF; Mahafza WS; Tarawneh ES
Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):291-7. PubMed ID: 21422628
[TBL] [Abstract][Full Text] [Related]
33. [Screening of cancer of the prostate: study in a Spanish population].
Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
[TBL] [Abstract][Full Text] [Related]
34. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
35. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis of prostate cancer with needle biopsy: should all cases be biopsied before treatment?
Oranusi CK; Ugezu AI; Nwofor A
Niger J Clin Pract; 2012; 15(1):48-50. PubMed ID: 22437089
[TBL] [Abstract][Full Text] [Related]
37. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
[TBL] [Abstract][Full Text] [Related]
40. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
